These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26831668)

  • 1. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
    Zhijun H; Shusheng W; Han M; Jianping L; Li-Sen Q; Dechun L
    Tumour Biol; 2016 Aug; 37(8):10257-67. PubMed ID: 26831668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice.
    Lamoine S; Cumenal M; Barriere DA; Pereira V; Fereyrolles M; Prival L; Barbier J; Boudieu L; Brasset E; Bertin B; Renaud Y; Miot-Noirault E; Civiale MA; Balayssac D; Aissouni Y; Eschalier A; Busserolles J
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.
    Li JP; Huang ZJ; Lu XS; Zhou YC; Shao Y; He XP; Chen SR; Wang DD; Qin LS; Sun WH
    Oncotarget; 2016 Nov; 7(47):77815-77824. PubMed ID: 27780925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
    Mishra VK; Wegwitz F; Kosinsky RL; Sen M; Baumgartner R; Wulff T; Siveke JT; Schildhaus HU; Najafova Z; Kari V; Kohlhof H; Hessmann E; Johnsen SA
    Nucleic Acids Res; 2017 Jun; 45(11):6334-6349. PubMed ID: 28369619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.
    Pinkerneil M; Hoffmann MJ; Kohlhof H; Schulz WA; Niegisch G
    Target Oncol; 2016 Dec; 11(6):783-798. PubMed ID: 27250763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo.
    Yang S; Li W; Sun H; Wu B; Ji F; Sun T; Chang H; Shen P; Wang Y; Zhou D
    BMC Cancer; 2015 Dec; 15():969. PubMed ID: 26674205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4SC-202 exerts an anti-tumor effect in cervical cancer by targeting PRLR signaling pathway.
    Zhang H; Li M; Sun H; Yang W; Ye M; Li H; Meng Y
    J Mol Histol; 2022 Dec; 53(6):891-902. PubMed ID: 36272045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
    Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
    Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel HDAC1 inhibitor, CBUD‑1001, exerts anticancer effects by modulating the apoptosis and EMT of colorectal cancer cells.
    Kim SL; La MT; Shin MW; Kim SW; Kim HK
    Int J Oncol; 2020 Oct; 57(4):1027-1038. PubMed ID: 32945468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo.
    Chen CH; Lee CH; Liou JP; Teng CM; Pan SL
    Oncotarget; 2015 Nov; 6(34):35991-6002. PubMed ID: 26462017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.
    Carson R; Celtikci B; Fenning C; Javadi A; Crawford N; Carbonell LP; Lawler M; Longley DB; Johnston PG; Van Schaeybroeck S
    Clin Cancer Res; 2015 Jul; 21(14):3230-3240. PubMed ID: 25813020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms.
    Zhang S; Deng Z; Yao C; Huang P; Zhang Y; Cao S; Li X
    PLoS One; 2017; 12(1):e0169585. PubMed ID: 28081222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells.
    Fu M; Wan F; Li Z; Zhang F
    Biochem Biophys Res Commun; 2016 Mar; 471(2):267-73. PubMed ID: 26773495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
    PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical study of cinobufagin as a promising anti-colorectal cancer agent.
    Lu XS; Qiao YB; Li Y; Yang B; Chen MB; Xing CG
    Oncotarget; 2017 Jan; 8(1):988-998. PubMed ID: 27894091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells.
    Wobser M; Weber A; Glunz A; Tauch S; Seitz K; Butelmann T; Hesbacher S; Goebeler M; Bartz R; Kohlhof H; Schrama D; Houben R
    J Hematol Oncol; 2019 Mar; 12(1):30. PubMed ID: 30885250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
    Minjie S; Defei H; Zhimin H; Weiding W; Yuhua Z
    Tumour Biol; 2015 Nov; 36(11):9015-22. PubMed ID: 26084607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
    Gaur S; Chen L; Ann V; Lin WC; Wang Y; Chang VH; Hsu NY; Shia HS; Yen Y
    Mol Cancer; 2014 Feb; 13():21. PubMed ID: 24495750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity.
    Jin ZZ; Wang W; Fang DL; Jin YJ
    Biochem Biophys Res Commun; 2016 Sep; 478(4):1515-20. PubMed ID: 27565731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.